GlobeNewswire by notified

Head-to-head Trial of Prolonged-Release Oral Ketamine Formulation, KET01, and Intranasal SPRAVATO®, Finds Less Incidence of Dissociation or Cardiovascular Effects with Oral Treatment, at doses used for Treatment-Resistant Depression


Results Suggest Formulation Potentially Suitable for At-Home Administration

Ketabon Also Releases In-Depth Data from Phase 2 KET01 Trial 

MUNICH, Germany, Nov. 13, 2023 (GLOBE NEWSWIRE) -- Ketabon GmbH (“Ketabon” or “the Company”), a joint venture between HMNC Brain Health and Develco Pharma, announced today favorable results from its head-to-head trial with KET01, the Company’s proprietary lead asset, versus SPRAVATO®, the FDA-approved intranasal spray for patients with Treatment-Resistant Depression (TRD). KET01 is an IP protected oral prolonged-release formulation of ketamine and is being studied in patients with TRD. Due to its unique metabolite profile, the incidence of dissociation with KET01 was very low and statistically significantly lower relative to SPRAVATO®, pointing to a clinically meaningful difference, which could offer the potential for a safe at-home unsupervised administration. During the summer Ketabon also released data from its Phase 2 KET01-02 trial with KET01, which demonstrated rapid and durable improvements in depressive symptoms in TRD. 

“KET01’s near complete absence of dissociative effects as measured by the Clinician-Administered Dissociative States Scale, suggests that the formulation can be suitable for administration outside of a medical setting, in the comfort of a patient’s home,” said HMNC Brain Health's Chief Medical Officer, Dr. Hans Eriksson. “As we are seeking alternative treatment options for patients suffering from TRD, we are hopeful KET01 has the potential to vastly change the treatment paradigm given its favorable tolerability at doses associated with antidepressant efficacy.”

Both studies were presented at the CNS Summit in Boston this week by Dr. Eriksson.

KET01-03 Versus SPRAVATO® Key Findings: 

The trial investigated the tolerability of a single dose of KET01 (240 mg) compared to intranasal esketamine (84 mg; active comparator) with respect to dissociative symptoms assessed by the change in Clinician-Administered Dissociative States Scale (CADSS) total score in healthy male subjects. Both doses are associated with antidepressant efficacy.

The trial was conducted under controlled conditions to investigate the tolerability of KET01 (ketamine) and SPRAVATO® (esketamine), with respect to dissociative symptoms, with emphasis on the time points after administration presumed for maximum plasma concentrations of ketamine and esketamine, respectively. A total of 26 participants at a single center were randomized to receive two single doses, KET01 (240 mg) and intranasal placebo nasal spray, or intranasal esketamine nasal spray (84 mg) and placebo tablet. All doses were sequence balanced, with a 2-to-4-week washout period between doses. No serious adverse effects were reported. 

KET01-02 Phase 2 Trial: Data Results of a Randomized Placebo-Controlled Double-Blind Phase 2 Trial

In August 2023, Ketabon revealed topline results from its Phase 2 trial of KET01, an oral prolonged-release ketamine formulation, which demonstrated early improvements in depressive severity and included minimal incidences of dissociation or cardiovascular effects. 

The trial investigated the efficacy, safety, and tolerability of KET01 in 122 outpatients with current major depressive episodes not responding to a minimum of two standard antidepressants, thereby fulfilling criteria for TRD. Patients were administered doses of 120 mg/day KET01, 240 mg/day KET01, or placebo given once daily in addition to their ongoing standard antidepressant treatment over a three-week period. The trial was conducted across 29 sites in Germany, Poland, and the Czech Republic.

Results showed that KET01, at a 240mg/day dose, demonstrated rapidly occurring and clinically relevant improvements in depressive severity 7 hours after the first dosing with a statistically significant separation on Day 4 and Day 7. The improvements from baseline were sustained while on active treatment until Day 21, and also after the 4-week follow-up period. The mean Montgomery-Åsberg Depression Rating Scale (MADRS) score improved in placebo-treated patients during the trial, but at the primary endpoint, after 21 days, the separation versus placebo did not reach statistical significance. Only minimal signs of dissociative symptoms were detected by the CADSS scale, and no changes in cardiovascular parameters were detected. 


  • There was no difference in mean CADSS scores between the groups at any assessment time point including during Day 1 when the scale was administered 1, 4, and 7 hours after dosing, with mean scores in the different treatment groups ranging from 0.2 to 1.3.
  • There was no difference in mean heart rate, diastolic blood pressure, or systolic blood pressure between the groups at any assessment time point, including during Day 1.
  • KET01 was well tolerated with treatment-emergent adverse events (TEAEs) reported by 47.5% of the placebo group, by 50.0% of the 120 mg/day KET01 group, and by 62.5% of the 240 mg/day KET01 group. The most commonly reported TEAEs per treatment arm were headache (17.5%) in the placebo group, headache (11.9%) in the 120 mg/day KET01 group; and dizziness (17.5%), in the 240 mg/day KET01 group.
  • TEAEs potentially related to dissociation were reported by 0% of the patients in the placebo group, by 0% of the patients in the 120 mg/day KET01 group, and by 12.5% of the patients in the 240 mg/day KET01 group.

“Data continues to suggest rapid and clinically relevant reduction of depressive symptoms after oral treatment with 240 mg/day of KET01. We believe that KET01 has the potential to be developed as an efficacious take-at-home treatment for TRD,” said Dr. Eriksson. “Together with the SPRAVATO head-to-head trial findings, it can be hypothesized that the low maximal ketamine concentration obtained with the prolonged-release oral ketamine formulation results in less dissociative effects and a positive benefit/risk, compared with ketamine-based treatments administered in a clinic.”

For additional details on the trial, please email For more information on the Ketabon program, please visit

About HMNC Brain Health 
HMNC Brain Health (HMNC Holding GmbH) is a global precision psychiatry biopharma company headquartered in Munich, Germany which is pioneering the development of personalized therapies powered by predictive companion diagnostics, leading to higher remission rates. The company develops a unique pipeline for targeting both Major Depressive Disorder (MDD) and Treatment-Resistant Depression (TRD). The company has presence in both Germany and the U.S. and is backed by a renowned global VC, several family offices, and a strategic healthcare investor. More information at

About Develco Pharma
Develco Pharma is a Swiss-German pharmaceutical company headquartered in Pratteln, Switzerland, specializing in the development and manufacture of orally administered modified, prolonged & chrono-release drugs containing known active ingredients. Established in 2006, today the company has a workforce of 130 employees. A state-of-the-art production facility for analgesics and drugs for the treatment of other indications has been in operation in Schopfheim, in Germany, since 2016. Develco identifies and defines pharmaceutical products containing known active ingredients and develops generic, hybrid, value-added, and innovative formulations backed by clinical data for the delayed or modified release of active ingredients. On the strength of its experience and innovativeness, the company has emerged as an internationally recognized provider of pharmaceuticals for the treatment of several disease areas. The customer base of Develco Pharma includes global pharmaceutical groups. The company has some 180 market approvals in all (products of different dosages) in Europe, the US, Middle East, South Africa, Asia, and Australia. More information at

About the Ketabon Program 
The Ketabon program, a joint venture between HMNC Brain Health and Develco Pharma comprises an oral prolonged-release formulation of ketamine for TRD (KET01) with minimal dissociative side effects, that could make it the first ketamine treatment for depression suitable for use at home. The pharmacokinetic profile of the prolonged-release formulation could significantly improve the risk profile and patient convenience, by minimizing dissociative side effects compared to the currently applied intravenous and intranasal ketamine therapies resulting in a decreased need for monitoring under medical supervision. TRD patients with insufficient response to standard antidepressants represent close to 30% of an overall estimated number of 320 million patients worldwide suffering from major depressive disorder. Clinical development of oral prolonged-release ketamine could also be potentially expanded into other indications beyond depression, such as anxiety, aggression, PTSD, and panic disorder.

Media contacts (U.S.):
McKenna Miller
Investor Contact (U.S.)
Sophia Bashford
+1 347-487-6788

To view this piece of content from, please give your consent at the top of this page.
To view this piece of content from, please give your consent at the top of this page.

About GlobeNewswire by notified

GlobeNewswire by notified
GlobeNewswire by notified
One Liberty Plaza - 165 Broadway
NY 10006 New York

GlobeNewswire by notified is one of the world's largest newswire distribution networks, specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media, investment community, individual investors and the general public.

Subscribe to releases from GlobeNewswire by notified

Subscribe to all the latest releases from GlobeNewswire by notified by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from GlobeNewswire by notified

Challenging conditions to persist, but expectation of clearer rate outlook and tightening bid-ask spreads on the horizon29.11.2023 01:00:00 CET | Press release

Industrial & logistics, multifamily, and office remain top picks for 2024 with investors deploying new strategies in each sector LONDON and TORONTO, Nov. 28, 2023 (GLOBE NEWSWIRE) -- The 2024 Global Investor Outlook released by Colliers (NASDAQ and TSX: CIGI) today reveals that challenging market conditions will persist into 2024, though expectations of a clearer rate outlook and tightening bid-ask spreads are on the horizon. Lower investment activity has constrained pricing discovery due to limited data points. As investors continue to seek stability in policy environments, industrial & logistics (I&L), multifamily and office sectors largely remain their top picks in the upcoming year. Pockets of opportunity are continuing to emerge as distress forces companies to unlock capital via sale and leasebacks, and property funds face redemption pressures. Furthermore, a record proportion (25%) of investors surveyed have ESG-based disposal and acquisition strategies in place – up from 10% jus

Nyxoah Strengthens its Executive Leadership Team28.11.2023 22:30:00 CET | Press release

Nyxoah Strengthens its Executive Leadership Team Francis Kim appointed as Chief Regulatory and Quality Officer Mont-Saint-Guibert, Belgium – November 28, 2023, 10:30pm CET / 4:30pm ET – Nyxoah SA (Euronext Brussels/Nasdaq: NYXH) (“Nyxoah” or the “Company”), a medical technology company focused on the development and commercialization of innovative solutions to treat Obstructive Sleep Apnea (OSA), today announced the appointment of Francis Kim as Chief Regulatory and Quality Officer. Francis will be leading Nyxoah’s Global Regulatory and Quality departments. Francis is a highly experienced global regulatory and quality executive in the healthcare industry, having spent more than 25 years in the medical device and life sciences sector. Francis has led Regulatory and Quality departments at Medtronic, Philips, and other companies, including introducing several innovative products and therapies to the market. “Nyxoah is entering the most exciting time in the Company’s history, with data fro

Alvotech Reports Financial Results for First Nine Months of 2023 and Provides Business Update28.11.2023 22:15:00 CET | Press release

Product revenue for the nine months of 2023 increased to $29.8 million, compared to $11.1 million for the same period in 2022Marketing authorization was received for AVT04 in Canada and Japan, the first for a biosimilar to Stelara® (ustekinumab)The European Medicines Agency proposed market authorization for AVT04 in the 30 member states of the European Economic Area, pending a final decision by the European CommissionApprovability of AVT02 and AVT04 in the U.S. now pending satisfactory US Food and Drug Administration (FDA) inspection of Alvotech’s facility in Iceland, currently expected on January 10 – 19, 2024Management will conduct a business update conference call and live webcast on Thursday November 29, 2023, at 8:00 am ET (13:00 pm GMT) Alvotech (NASDAQ: ALVO, or the “Company”), a global biotech company specializing in the development and manufacture of biosimilar medicines for patients worldwide, today reported unaudited financial results for the first nine months of 2023 and pr

RÄTTELSE: Saknad MAR-etikett i tidigare pressmeddelande – ”Anoto ingår ett avtal för 1,1 miljoner USD avseende försäljning av pennor och treåriga mjukvarulicenser med Deutsche Telekom”28.11.2023 19:15:00 CET | Pressemelding

Anoto Group AB (publ) utfärdar en rättelse av pressmeddelandet som publicerades tidigare idag. Rättelsen avser att pressmeddelandet saknade MAR-etikett med hänvisning till EU:s marknadsmissbruksförordning (MAR). Följande information skulle ha varit med i pressmeddelandet: ”Denna information är sådan information som Anoto Group AB (publ) är skyldigt att offentliggöra enligt EU:s marknadsmissbruksförordning. Informationen lämnades genom ovanstående kontaktpersons försorg för offentliggörande den 28 november 2023, kl. 08:00 CEST.” Nedan publiceras det korrekta pressmeddelandet i sin helhet. Stockholm den 28 november 2023 – Anoto Group AB (publ) ("Anoto" eller "Bolaget") meddelar idag att bolaget har tecknat ett upphandlingsavtal som avser försäljning av nya pennor, samt ett treårigt mjukvarulicensavtal med Deutsche Telekom AG (”Deutsche Telekom”). Deutsche Telekom är en av de äldsta kunderna inom Anotos affärssegment Forms och avtalet innebär att ramverket inom vilket Anoto och Deutsche T

CORRECTION: Missing MAR label in previous press release – “Anoto enters into a USD 1.1 million agreement for the sale of pens and three-year software licenses with Deutsche Telekom”28.11.2023 19:15:00 CET | Press release

Anoto Group AB (publ) issues a correction to the press release published earlier today. The correction refers to the fact that the press release lacked a MAR label with reference to the EU Market Abuse Regulation (MAR). The following information should have been included in the press release: ”This information constitutes inside information as Anoto Group AB (publ) is obliged to disclose under the EU Market Abuse Regulation 596/2014. The information was provided by the contact person above for publication 28 November 2023, at 08:00 CEST.” The correct press release is published in its entirety below. Stockholm, 28 November 2023 – Anoto Group AB (publ) ("Anoto" or the "Company") today announces that it has signed a procurement agreement relating to the sale of new pens, plus a new three-year software licensing agreement with Deutsche Telekom AG (“Deutsche Telekom”). Deutsche Telekom is one of the oldest customers of Anoto’s Forms business and this agreement means that the framework withi